Recent Quotes (30 days)

You have no recent quotes
chg | %

AEterna Zentaris Inc. (USA)  

(Public, NASDAQ:AEZS)   Watch this stock  
Find more results for AEZS
0.612
Dec 19 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 0.48 - 1.62
Open     -
Vol / Avg. 0.00/1.56M
Mkt cap 35.01M
P/E     -
Div/yield     -
EPS -0.65
Shares 63.91M
Beta 1.39
Inst. own 28%
Mar 18, 2015
Q4 2014 AEterna Zentaris Inc Earnings Release (Estimated) Add to calendar
Nov 5, 2014
Q3 2014 AEterna Zentaris Inc Earnings Call
Nov 4, 2014
Q3 2014 AEterna Zentaris Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin - -441.13%
Operating margin - -444.96%
EBITD margin - -404.53%
Return on average assets -85.07% -42.94%
Return on average equity -528.45% -525.41%
Employees 76 -
CDP Score - -

Address

1405 du Parc-Technologique Blvd
QUEBEC, QC G1P 4P5
Canada
+1-418-6528525 (Phone)
+1-418-9489191 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Aeterna Zentaris Inc. is a late-stage drug development company specialized in oncology and endocrine therapy. The Company�s pipeline encompasses compounds at all stages of development, from drug discovery through to marketed products. The development priorities in oncology are the completion of Phase 3 trials with perifosine in colorectal cancer (CRC) and in multiple myeloma (MM), as well as the further advancement of AEZS-108, for which it has completed a Phase 2 trial in advanced endometrial and advanced ovarian cancer. Its pipeline also encompasses other earlier-stage programs in oncology. AEZS-112, which is an oral anticancer agent, which includes three mechanisms of action (tubulin, topoisomerase II and angiogenesis inhibition) has completed a Phase 1 trial in advanced solid tumors and lymphoma.

Officers and directors

David A. Dodd Chairman of the Board, President, Chief Executive Officer
Age: 64
Bio & Compensation  - Reuters
Dennis Turpin CA Chief Financial Officer, Senior Vice President
Bio & Compensation  - Reuters
Richard Sachse M.D., Ph.D. Senior Vice President, Chief Scientific Officer, Chief Medical Officer
Bio & Compensation  - Reuters
Jude Dinges Chief Commercial Officer, Senior Vice President
Bio & Compensation  - Reuters
Philip A. Theodore Senior Vice President, Chief Administrative Officer, Corporate Secretary
Age: 60
Bio & Compensation  - Reuters
Amelie Metivier Assistant Secretary
Bio & Compensation  - Reuters
Juergen H. L. Ernst Lead Director
Age: 75
Bio & Compensation  - Reuters
M. Marcel Aubut QC Independent Director
Bio & Compensation  - Reuters
Jose P. Dorais Independent Director
Bio & Compensation  - Reuters
Carolyn Egbert Independent Director
Bio & Compensation  - Reuters